文献速递胸部肿瘤

SN-38抗Trop-2抗体药物偶联物Sacituzumab Govitecan治疗晚期非小细胞肺癌

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
PubMed 文献 · J Clin Oncol · 2017-05-26

这项单臂多中心试验评估了Sacituzumab Govitecan(IMMU-132)在经治转移性非小细胞肺癌患者中的安全性和客观缓解率,54例患者接受8或10 mg/kg治疗。可评估人群客观缓解率为19%,中位缓解持续时间6.0个月,中位无进展生存期5.2个月,中位总生存期9.5个月,≥3级不良事件以中性粒细胞减少(28%)最常见。作者认为该药耐受性良好并产生持久缓解,应进一步研究。

要点

  • 经治转移性非小细胞肺癌中,可评估人群客观缓解率为19%,疾病控制率43%。
  • 中位无进展生存期5.2个月,中位总生存期9.5个月。
  • ≥3级不良事件包括中性粒细胞减少28%、腹泻7%、恶心7%、疲乏6%、发热性中性粒细胞减少4%。

核心结论

  • IMMU-132在经治转移性非小细胞肺癌患者中耐受性良好并产生持久缓解,作者认为应进一步研究该抗体药物偶联物。

研究设计与样本

  • 单臂多中心试验,纳入经治转移性非小细胞肺癌患者,第1天和第8天给予8或10 mg/kg,21天为一周期。
  • 共54例患者接受治疗,可评估人群47例,中位既往治疗线数为3线(范围2至7线)。

主要发现

  • 可评估人群客观缓解率为19%,中位缓解持续时间6.0个月(95%CI 4.8至8.3个月),临床获益率43%。
  • 意向治疗人群客观缓解率为17%(9/54),中位缓解起效时间3.8个月,包括免疫检查点抑制剂治疗后复发或进展的患者。
  • 意向治疗人群中位无进展生存期5.2个月(95%CI 3.2至7.1个月),中位总生存期9.5个月(95%CI 5.9至16.7个月)。
  • ≥3级不良事件包括中性粒细胞减少28%、腹泻7%、恶心7%、疲乏6%、发热性中性粒细胞减少4%。
  • 26份可评估存档肿瘤标本中超过90%经免疫组化检测Trop-2高表达(2+、3+),提示Trop-2不是疗效预测生物标志物。

局限性

  • 原文未报告局限性,但作者在结论中提出该抗体药物偶联物应进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Trop-2, expressed in most solid cancers, may be a target for antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC). We studied sacituzumab govitecan (IMMU-132), a Trop-2 ADC, for the targeting of SN-38. Patients and Methods We evaluated IMMU-132 in a single-arm multicenter trial in patients with pretreated metastatic NSCLC who received either 8 or 10 mg/kg on days 1 and 8 of 21-day cycles. The primary end points were safety and objective response rate (ORR). Progression-free survival and overall survival were secondary end points. Results Fifty-four patients were treated. In the response-assessable study population (n = 47), which had a median of three prior therapies (range, two to seven), the ORR was 19%; median response duration, 6.0 months (95% CI, 4.8 to 8.3 months); and clinical benefit rate (complete response + partial response + stable disease ≥ 4 months), 43%. ORR in the intention-to-treat (ITT) population was 17% (nine of 54). Responses occurred with a median onset of 3.8 months, including patients who had relapsed or progressed after immune checkpoint inhibitor therapy. Median ITT progression-free survival was 5.2 months (95% CI, 3.2 to 7.1 months) and median ITT overall survival, 9.5 months (95% CI, 5.9 to 16.7 months). Grade 3 or higher adverse events included neutropenia (28%), diarrhea (7%), nausea (7%), fatigue (6%), and febrile neutropenia (4%). One patient developed a transient immune response, despite patients receiving a median of 10 doses. More than 90% of 26 assessable archival tumor specimens were highly positive (2+, 3+) for Trop-2 by immunohistochemistry, which suggests that Trop-2 is not a predictive biomarker for response. Conclusion IMMU-132 was well-tolerated and induced durable responses in heavily pretreated patients with metastatic NSCLC. This ADC should be studied further in this disease and in other patients with Trop-2-expressing tumors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Heist RS, Guarino MJ, Masters G, et al. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017. PMID: 28548889. doi:10.1200/JCO.2016.72.1894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。